University Staff Directory The University of Adelaide Australia
Faculties & Divisions | People A to Z | Media Expertise | Phonebook
Public browsing [Login]
Text Zoom: S | M | L

Professor Sandra Hodge

Telephone +61 8 8222 3443
Position Head - COPD Research Group Lung Research Unit
Email sandra.hodge@health.sa.gov.au
Building IMVS - Hanson Institute Building
Floor/Room 1
Campus Institute of Medical & Veterinary Science
Org Unit Medical Specialties

To link to this page, please use the following URL:
http://www.adelaide.edu.au/directory/sandra.hodge

Biography/ Background

Professor Sandra Hodge

Professor Hodge heads the Chronic Inflammatory Lung Disease Research Group within the Lung Research Unit at the Hanson Institute/Royal Adelaide Hospital and is recognised internationally as the first to describe the concept of failed efferocytosis and its pro-inflammatory consequences in the airway in COPD. She has published over 100 refereed manuscripts and 150 refereed conference papers. All are published in ‘ERA Quality’ Journals with over 2,500 citations by world-renowned experts and in top ranking journals. Her work has resulted in several invitations to Industry Drug Discovery meetings and has formed the basis for a great deal of subsequent research in this field.

Relevant publications:

1. Hodge S et al. Azithromycin Improves Macrophage Phagocytic Function and Expression of Mannose Receptor in COPD. Am J Respir Crit Care Med 2008;178(2):139-48. This important publication significantly added to the body of knowledge upon which the use of macrolides as anti-inflammatory therapies in lung disease is based and provided a substantial basis for the establishment of a multi-centre NHMRC funded trial of macrolides in asthma. AJRCCM is the principle journal in its field.

2. Hodge S, et al. Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophages in chronic obstructive pulmonary disease subjects. Respirology 2012;17(5):802-7. This manuscript reporting further positive effects of macrolides in COPD is one of 7 that have emerged from her involvement in clinical studies of macrolides (featured in MDLinx; subject of editorial (Respirology 2013:17:p739) by P Hansbro a respected researcher in the field)

3. Hodge S, et al. Is there a therapeutic role for mannose binding lectin in cigarette smoke-induced lung inflammation? Evidence from a murine model. Am J Respir Cell Mol Biol 2010;42:235-42 
4. Cigarette Smoke-Induced Changes to Alveolar Macrophage Phenotype and Function Are Improved by Treatment with Procysteine. Am J Respir Cell Mol Biol 2011;44:1- 9.
5. Mukaro V et al. Lectins offer new perspectives in the development of macrophage-targeted therapies for COPD/emphysema PLoS One 2013;8(2):e56147

These manuscripts describe the identification of new and novel adjunct macrophage-targeted therapies for the treatment of COPD and are shaping current concepts on therapeutic approaches as evident by the increasing number of requests for industry collaborations in this regard. Already the findings described in these manuscripts have formed the basis for clinical trials, international collaborations and grant success. Two publications were selected for Faculty of 1000 medicine; another identified as being of special interest to the drug development sector and featured online http://globalmedicaldiscovery.com, others were
invited for presentation in an International Innovation Report, featured on MDLinx and Pubadvanced.

Grants: Since 2000, CI Hodge’s salary, and those of her team have been 100% funded by competitive grants (>$9 million as CI). These include Major national grants (NHMRC: 8 as CI; 4 CIA), National grants from specialist agencies (Last 5 years: Australian Respiratory Council, Australian Lung Foundation (ALF), Cancer Council, CellCept, Thoracic Society of Australia and New Zealand (TSANZ), Channel 7, and state competitive schemes.

Peer Recognition: International

Invited Speaker:

National Jewish Medical Research, Denver, USA (2009).

University of Denver, USA (2009).

Le Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Switzerland (2013, 2014).

AFCG (2005) Presidential address.

American Thoracic Society (2010)-keynote speaker (Symposium “Coins for the Boatman: Is there a relationship between cell death, removal and disease?”)*.

Int. Lectin Society (2011)-keynote speaker (Symposium “Clinical aspects of lectin biology”).

Australasian Flow Cytometry Group (AFCG)/Australian Society Immunology/HLDA (2004).

Asia Pacific Society of Respirology/American College of Chest Physicians Invited speaker (2007)

American Thoracic Society Invited speaker (2010).

ERS COPD Research Award Ceremony Session Chair (2012).

ERS Hot Topic “Innate and adaptive immunity in COPD” Session Chair (2012).

International Conference Organizing Committees

·   American Thoracic Society (2010).

·   Asia Pacific Society of Respirology/American College of Chest Physicians (2004).

·   AFCG/ASI/The human leucocyte differentiation antigens (HLDA) workshops (2004).

·   Federation of Immunological Societies of Asia-Oceania (2004).

International Advisory Role: AstraZeneca R&D Sweden (2011-2012); AMGEN (2014); GlaxoSmithkline (USA) COPD Drug Discovery group (2008).

Editorial Board international journals J Pulmonary Respir Med; Inflam & Allergy–Drug Targets.

Chief Book Editor: Bentham Science Publishers (2009).

Peer recognition: National

Invited Speaker TSANZ (2007, 2008), Australasian Flow Cytometry Group (AFCG) (2000, 2004), Newcastle Asthma Meeting (2008), Woolcock Institute (2013) Lyceum Club (2014).

Member major health policy advisory group TSANZ Education and Research, and Research sub-committees; representing NHMRC: ‘Science Meets Parliament’ Canberra, (2008), Parliamentary Select Committee on E-cigarettes (2015)

Committee memberships RAH/Hanson Institute Equipment Advisory Committee (2012-present).

National Secretary and National President AFCG.

Awards: National: TSANZ & Asthma Australia Career Travel Award (2014).

TSANZ Robert Pierce Grant in Aid for Indigenous Lung Health (2013).

·   Australian Respiratory Council Harry Windsor Award (2009).

·   ALF/Webster COPD Research Award (2008).

·   TSANZ/Allan Hanbury’s Respiratory Research Fellowship (2005).

·   ALF/Boehringer Chronic Airflow Limitation Research Fellowship (2002).

·   Hanson Institute Early Career Researcher of the Year (2008).

·   TSANZ SA Young Investigator Award.

Research Translation/ Clinical Activities

·   CI clinical trials: RAH COPD azithromycin study (2008).

·   CI in large multicentre clinical trial: CI and substudy leader NHMRC569246 (2009-14).

·   Community/health services: Media presentations, weekly screening clinics for smokers.

Public Health Activities- Prestigious public health policy forums.

·   Science Meets Parliament, representing NHMRC (2008).

·   TSANZ Education and Research sub-committee member (2010-2011).

·   TSANZ Research subcommittee member (2012-current).

Contribution to Research Training- Primary supervisor of 4 and joint supervisor of 13 postgraduate students; mentor to over 30 postdoctoral and research staff.

Organiser local and national training programs

·   Federation of Immunological Societies of Asia-Oceania specialised flow cytometry workshop.

·   AFCG/Australian Society Immunology/ HLDA workshop.

Contribution to Profession

·   Member NHMRC GRP (2012-2014)

·   Reviewer International Granting Bodies British Lung Foundation, Wellcome Trust, Chronic GDRT UK, Medical Research Council UK, Hong Kong Grants Committee.

·   Reviewer for all the top respiratory journals and several high impact general journals.

·   Reviewer National Granting Bodies- over 20 including NHMRC, Alfred Health, Actelion, Dust Diseases Board, ALF, TSANZ, Boehringer, Asthma Foundation, Astra Zeneca, Ludwig Engel.

·   Reviewer PhD 5 Australian Universities.

·   Editorial Board Member 2 Int. Journals: J Pulm & Respir Med, Inflam & Allergy–Drug Targets.

·   Invited Chief Book Editor Macrophages in Chronic Lung Disease, Bentham 2010.

 

 

 

 

Files

Expertise for Media Contact

CategoriesMedicine & Medical Research
Expertisechronic obstructive pulmonary disease [COPD]; emphysema; asthma; cell biology; novel therapies
NotesMy research has attracted >$9 million funding and translation to 2 clinical trials. International invitations include plenary speaker, session chair, conference organizing committees, policy meetings and journal editorial boards. Prestigious awards include ALF, Allan Hanburys, Boehringer, Hanson Institute. Industry engagement includes Advisor AstraZeneca R&D and GSK COPD Drug Discovery group.

Entry last updated: Thursday, 18 Feb 2016

The information in this directory is provided to support the academic, administrative and business activities of the University of Adelaide. To facilitate these activities, entries in the University Phone Directory are not limited to University employees. The use of information provided here for any other purpose, including the sending of unsolicited commercial material via email or any other electronic format, is strictly prohibited. The University reserves the right to recover all costs incurred in the event of breach of this policy.